So far, two antibodies are approved as targeted immunotherapies in combination with a platinum‐based chemotherapy in patients with advanced, metastatic or recurrent cervical cancer: bevacizumab, an anti‐VEGF antibody to inhibit angiogenesis [48], and pembrolizumab, an anti‐PD‐1 antibody [49]. Here, PDCD1 is linked to cervical cancer.